Clinical Research Directory

Inclusion Criteria: * Patient with locally advanced or post-operative ENT cancer with high risk of recurrence * Patient ≥ 18 years * Absence of prior chemotherapy or radiotherapy * Patient eligible for chemotherapy with cisplatin according to the standard regimen: radiotherapy delivering 60-70 Gy in 30-35 fractions spread over 6 to 7 weeks associated with chemotherapy with cisplatin 100 mg/m2 every 3 weeks (i.e. at week 1, 4 and 7) * Patient ineligible for cisplatin chemotherapy receiving: * Either exclusive radiotherapy (age \> 70 years, contraindication: renal failure, patient wearing a device): radiotherapy delivering 60-70 Gy in 30-35 fractions spread over 6 to 7 weeks. * either chemoradiotherapy with a chemotherapy protocol different from the standard scheme (due to a contraindication to cisplatin): radiotherapy delivering 60-70 Gy in 30-35 fractions spread over 6 to 7 weeks associated with non-standard chemotherapy ototoxic (cetuximab or carboplatin-5FU) Exclusion Criteria: * Tinnitus grade ≥ 2 according to the SOMA-LENT scale * Patient fitted for hearing disorders * Significant cognitive disorders that may compromise the performance of the various assessments * Patients treated with weekly cisplatin * Patient's refusal to participate in research